This study is the first to combine a PD-L1 inhibitor and CTLA4 inhibitor to prolong the survival of patients with pMMR/MSS advanced refractory CRC, raising new hopes for immunotherapy for pMMR/MSS mCRC. Here, CTLA4 is linked to colorectal carcinoma.